SMAD3 and myotonic dystrophy type 2: More specifically, deletion of Smad3 simultaneously improves pancreatic β cell function, apoptosis, and systemic insulin resistance with the consequence of eliminated overt diabetes in diabetic mouse models (69–71), revealing Smad3 as a key mediator and ideal therapeutic target for DM2.